| scholarly article | Q13442814 |
| P50 | author | Greg N. Fuller | Q37370656 |
| Michael D Prados | Q114338680 | ||
| P2093 | author name string | Li Zhang | |
| Christopher E Pelloski | |||
| Susan Chang | |||
| Howard Colman | |||
| Kenneth D Aldape | |||
| W K Alfred Yung | |||
| Dima Suki | |||
| Amy B Heimberger | |||
| Juinn-Lin Liu | |||
| E Lin | |||
| Fredrick G Barker | |||
| Shaio Y Woo | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3935-3941 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. | |
| P478 | volume | 12 |
| Q47784163 | A Rationale for Targeting Extracellular Regulated Kinases ERK1 and ERK2 in Glioblastoma |
| Q26849503 | A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy |
| Q27312887 | A drosophila model for EGFR-Ras and PI3K-dependent human glioma |
| Q33900952 | A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications |
| Q34105105 | Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma |
| Q48347764 | Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival |
| Q38014949 | Advances in malignant glioma drug discovery |
| Q47996715 | Association between Phosphorylated AMP-Activated Protein Kinase and MAPK3/1 Expression and Prognosis for Patients with Gastric Cancer |
| Q39700712 | Association between YKL-40 and adult primary astrocytoma |
| Q44789789 | Biological pathway selection through nonlinear dimension reduction |
| Q43053159 | CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. |
| Q99417962 | Chitinase-3 like-protein-1 function and its role in diseases |
| Q35242525 | Chitinases in the salivary glands and circulation of patients with Sjögren's syndrome: Macrophage harbingers of disease severity |
| Q37601254 | Combining drugs and radiotherapy: from the bench to the bedside |
| Q37643431 | Common corruption of the mTOR signaling network in human tumors |
| Q37675836 | Correlation of Chitinase 3-Like 1 Single Nucleotide Polymorphisms with Hepatocellular Carcinoma in Taiwan |
| Q44387794 | Diagnostic and prognostic molecular markers in common adult gliomas |
| Q35566228 | Drosophila melanogaster as a model system for human brain cancers |
| Q55460776 | EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers. |
| Q37186651 | EWS Knockdown and Taxifolin Treatment Induced Differentiation and Removed DNA Methylation from p53 Promoter to Promote Expression of Puma and Noxa for Apoptosis in Ewing's Sarcoma |
| Q35008709 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma |
| Q37038176 | Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung |
| Q43011817 | Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer |
| Q24618080 | Enhancing Diagnosis, Prognosis, and Therapeutic Outcome Prediction of Gliomas Using Genomics |
| Q33818584 | Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma |
| Q48450513 | Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades |
| Q55463212 | Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome. |
| Q36735677 | Gene Encoding Chitinase 3-Like 1 Protein (CHI3L1) is a Putative Oncogene |
| Q38225874 | Glioblastoma multiforme: State of the art and future therapeutics |
| Q80914233 | Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy |
| Q39908058 | Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress |
| Q34167071 | High expression of mTOR is associated with radiation resistance in cervical cancer |
| Q36500396 | High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era |
| Q49190145 | Identification of expression quantitative trait loci of MTOR associated with the progression of glioma |
| Q53499450 | Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme |
| Q37435455 | Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas |
| Q30441231 | Immunohistochemical assessment of protein phosphorylation state: the dream and the reality |
| Q38618205 | Implications of mitogen-activated protein kinase signaling in glioma. |
| Q35841656 | Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells |
| Q54979176 | Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs. |
| Q58215000 | Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures |
| Q36709555 | Is YKL-40 a new therapeutic target in cancer? |
| Q27851755 | Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. |
| Q39618772 | MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions |
| Q41962843 | MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma |
| Q33925544 | Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies |
| Q38233134 | Molecular prognostic factors in glioblastoma: state of the art and future challenges |
| Q36829847 | Molecularly targeted therapy for malignant glioma |
| Q37974367 | Molecularly targeted therapy in neuro-oncology |
| Q31148172 | Network-constrained regularization and variable selection for analysis of genomic data |
| Q47867724 | Overexpression of mTOR and p(240-244)S6 in IDH1 Wild-Type Human Glioblastomas Is Predictive of Low Survival |
| Q24322118 | PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma |
| Q33747609 | Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma |
| Q36544089 | Phospho-ERK1/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma |
| Q54504827 | Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas. |
| Q37605869 | Plasma YKL-40: a potential new cancer biomarker? |
| Q33311133 | Predictive and prognostic markers in neuro-oncology |
| Q37444920 | Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. |
| Q37733727 | Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer. |
| Q39523783 | Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer |
| Q38203283 | Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment |
| Q35013574 | Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma |
| Q34250109 | Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer |
| Q43154532 | Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas |
| Q34939141 | Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency |
| Q33407127 | Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. |
| Q24632928 | Recent advances in the molecular understanding of glioblastoma |
| Q33732189 | Resveratrol represses YKL-40 expression in human glioma U87 cells |
| Q24295370 | Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma |
| Q39950004 | Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. |
| Q37174303 | Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas |
| Q37761935 | Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics |
| Q34234351 | Survivin knockdown increased anti-cancer effects of (−)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells |
| Q37699420 | Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma |
| Q90317496 | Synergic pro-apoptotic effects of Ferulic Acid and nanostructured lipid carrier in glioblastoma cells assessed through molecular and Delayed Luminescence studies |
| Q36428239 | Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells |
| Q43272233 | Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-a |
| Q38186656 | Targeted therapy in gliomas |
| Q35864082 | The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas |
| Q37815546 | The Use of Global Profiling in Biomarker Development for Gliomas |
| Q35214534 | The challenges and the promise of molecular targeted therapy in malignant gliomas |
| Q39176294 | The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma |
| Q34729001 | The expression of cytoglobin as a prognostic factor in gliomas: a retrospective analysis of 88 patients |
| Q34886859 | The mTOR signaling pathway as a treatment target for intracranial neoplasms |
| Q38179983 | The significance of YKL-40 protein in liver fibrosis |
| Q36485266 | The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas |
| Q39337955 | Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer |
| Q37809998 | Tumor Profiling: Development of Prognostic and Predictive Factors to Guide Brain Tumor Treatment |
| Q39501439 | Valproic Acid Induced Differentiation and Potentiated Efficacy of Taxol and Nanotaxol for Controlling Growth of Human Glioblastoma LN18 and T98G Cells |
| Q80819347 | What is the relevance of determining EGFR-variant-III status in glioblastomas? |
| Q38882167 | Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways |
| Q33719157 | YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas |
| Q21260376 | YKL-40 tissue expression and plasma levels in patients with ovarian cancer |
| Q37636543 | YKL-40--an emerging biomarker in cardiovascular disease and diabetes |
| Q37334247 | YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? |
| Q39208882 | mTOR pathway as a potential target in a subset of human medulloblastoma |
Search more.